MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2024 International Congress

    Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD

    E. Iglesias-Camacho, FJ. Gómez Campos, P. Franco Rosado, L. Garrote Espina, AM. Castellano-Gerrero, M. San Eufrasio, C. Perez-Calvo, L. Muñoz-Delgado, S. Jesús, D. Macías-García, E. Ojeda-Lepe, A. Adarmes-Gómez, F. Carrillo, JF. Martín-Rodriguez, P. Mir (Seville, Spain)

    Objective: To identify EEG source level differences between patients with Parkinson's disease (PD) and associated impulse control disorders (ICD) and patients without ICD. Background: Previous…
  • 2024 International Congress

    Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.

    D. Ortiz-Zacarias, S. Castillo-Torres, M. Cansino-Torres, J. Trejo-Ayala, B. Chávez-Luevanos, I. Estrada-Bellmann (Monterrey, Mexico)

    Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…
  • 2024 International Congress

    In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease

    C. Mahapatra (Mumbai, India)

    Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…
  • 2024 International Congress

    Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.

    B. Mukhammedaminov (Uzbekistan, Uzbekistan)

    Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…
  • 2024 International Congress

    Medication Refractory Restless Legs Syndrome: Real-World Experience

    P. Petramfar, J. Jankovic (Houston, USA)

    Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…
  • 2024 International Congress

    A case of Restless Abdominal Syndrome An Uncommon Variant of Restless Leg Syndrome

    M. Avanaki, D. Salzman (Weston, USA)

    Objective: To identify restless abdominal syndrome as a potential cause of abdominal discomfort in patients presenting with discomfort in abdominal area which gets worse at…
  • 2024 International Congress

    AI for Personalized Medication Management in Parkinson’s Disease

    R. Diaz-Rincon, H. Khoshbouei, B. Shickel (Gainesville, USA)

    Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…
  • 2024 International Congress

    Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line

    J. Hall, R. Islam, D. Nolasco, B. Carr (GAINESVILLE, USA)

    Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…
  • 2023 International Congress

    Impulse Control Disorder and medication management in Patients with Early-Onset Parkinson’s Disease

    J. Jacobson, K. Ghoniem, A. Mullan, P. Turcano, C. Stang, E. Camerucci, C. Piat, J. Bower, R. Savica (Rochester, USA)

    Objective: To assess the usage frequency of dopamine agonists (DA), the prevalence of impulse control disorder (ICD) in patients with Early-onset Parkinson’s Disease (EOPD), and…
  • 2023 International Congress

    The role of depression in the development of Impulse Control Disorders in Parkinson´s Disease.

    M. Vales Montero, F. Ferre Navarrete, J. Conejo Galindo, P. Melgarejo Otálora, P. Andrés Camarón, J. Suárez Campayo, R. Reyes Marrero, JR. López-Trabada Gómez, MB. Díaz Rodríguez, F. Grandas (Madrid, Spain)

    Objective: We aimed to investigate whether depression is associated with a higher risk of developing impulse control disorders (ICD) in Parkinson´s disease (PD) patients and…
  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley